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Abstract 
Background: Evolution of individualized radiosurgical therapeutic methods for brain metastasis as an ominous 
prognostic finding may encourage a more extensive application of neuroimaging in patients with extracerebral 
cancer. The aim of the present study was to investigate the added value of brain-included 18 F FDG PET/CT 
acquisition protocol based on primary cancer type and clinical indication. 
Materials and Methods: A retrospective review was performed on 3945 18 F FDG PET/CT reports of patients 
with extra-cerebral cancer underwent brain-included PET/CT study. Cerebral lesions suggestive of brain 
metastasis were subsequently verified by MRI, MRI+MRS, surgical pathology and a 1-year clinical formal 
follow up. The detection rate of new brain metastasis and related impact on disease status were then 
investigated in each cancer type based on clinical indication. 
Results: Of a total 3933 eligible patients, 44 (1.12%) were finally verified to have new cerebral metastasis. 
The most common primary sources were lung cancer (19/385, 4.93%), cancer of unknown primary (CUP) 
(5/168, 2.97%) and breast cancer (8/468, 1.71%). The most common clinical indications were initial staging 
(17/44, 43.1%) and restaging (19/44, 36.4%). Change in disease status occurred in 12 out of 44 patients 
(27.3%), more frequently occurred in lung cancer (n=4), in all indications and breast (n=3) cancers at 
restaging (n=7, 43.8%). 
Conclusion: PET/CT acquisition protocol study may be best optimized based on the type of primary cancer and 
timing of evaluation. Brain-included field of view may be recommended for lung cancer regardless the clinical 
indication, cancer of unknown primary and breast cancer at restaging. 
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Introduction 
Increasing incidence of brain metastasis in addition 
to the advent of individualized surgical and 
radiosurgical therapeutic methods may highlight the 
role of neuroimaging modalities in early detection of 
clinically silent cerebral metastasis and related 
impact on quality of life and survival in extracerebral 
cancer patients. Currently, there is no consensus on 
routine screening of cerebral metastasis in 
neurologically asymptomatic patients, expect for 
lung cancer and metastatic melanoma1. Whole body 
18 FDG PET/CT, as the most comprehensive 
imaging modality in oncology has gained wide 
acceptance in clinical practice. The most prevalent 
primary origins of brain metastasis, including lung, 
breast, melanoma, colorectal and kidney2 often 
constitute the vast majority of patients’ population at 
most PET/CT center, worldwide. However, evidence 
for optimizing PET/CT field of view and potential 
value of brain-included acquisition in oncologic 
studies are scarce. The results of preliminary studies 
most of which were performed on the small 
population with stand-alone PET did not advocate 
the routine inclusion of brain in 18F FDG PET 
studies due to the little clinical impact3. Despite the 
inherently low sensitivity of brain PET due to high 
physiologic cerebral 18F FDG uptake obscuring 
small sized brain metastasis4. But recent large-scaled 
studies using high resolution hybrid PET/CT scanner, 
with or without contrast enhancement, have been 
indicated that brain-included whole body PET/CT 
may provide additional valuable information about 
previously unsuspected brain metastasis in certain 
cancer5-8 which may potentially contribute to a 
timely treatment and better survival. Few studies 
have been investigated the added value of PET-
detected brain metastasis on the basis of cancer type 
and timing of evaluation6-7, 9-11. Our observations on 
over 3000 brain-included PET/CT study advanced a 
proposal for a cancer-specified stratification method 
to optimize PET/CT acquisition protocol. The aim of 
the present study was to investigate the added value 
of brain-included PET/CT study in detection of 
previously unidentified cerebral metastasis and 
related impact on disease status based on the primary 
cancer type and clinical indication. 
Methods 
Patients: The Institutional Review Board at Shahid 
Beheshti University of Medical Science approved this 
retrospective study and waived the need for informed 
consent.  
A retrospective review was performed on 4004 
patients underwent brain-included whole body 
PET/CT studies in Masih Daneshvari Hospital 
between May 2012-Mar 2015. Of these, 8 patients 
were referred for non-oncologic neurological 
indications, 63 were known case of primary (n=25) or 
metastatic (n=38) cerebral tumor and hence were 
excluded from the study. A total of 3933 patients with 
extra-cerebral cancer were considered for inclusion in 
this study. Brain metastasis was reported in 65 
patients, 21 of which lost to complete clinical formal 
follow up. Finally 46 patients constituted the study 
cohort. All demographic and cancer related 
characteristics including age, gender, primary cancer 
type and reason for referral were recorded.  
PET/CT acquisition protocol: Whole body F-18 
FDG PET/CT was performed using an integrated 
PET/CT scanner (GE 690 Discovery, 64 Slice, Time 
of Flight). Fasting period was considered at least 8 
before injection for adults. Blood glucose level was 
below 150 mg/dl at the time of radiotracer injection. 
Sixty minutes (± 10%) after IV administration of 
4.6MBq/Kg (0.12 mCi/Kg F-18 FDG, CT acquisition 
commenced craniocuadally from high vertx to mid-
thigh (or to toe as indicated) with a multidetector CT 
scanner and the following parameters: auto mAs 50-
120, 120 kV, noise factor 19, 2.5 mm thickness. Thirty 
minute before imaging acquisition, 40cc meglumin 
76% (containing 370mg Iodine /cc) in 1500 water was 
administered as oral contrast in adults. The PET data 
were then collected in the reverse direction 
immediately after CT acquisition with time of 3 
minutes per bed position. The PET raw data were 
corrected for attenuation, dead time, random and 
scatter coincidence, and subsequently reconstructed by 
iterative method and HD (high definition) technique. 
No premedication was administrated before injection. 
Image interpretation: All the image data set of 
selected patients including AC and NAC PET, CT and 
fused PET/CT were retrieved on PACS and reviewed 
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by a team comprised of an experience radiologist and 
a nuclear medicine physician on advantage window 
Volume Share 4.5, side-by side and reached at 
consensus for the presence of cerebral metastasis. 
Disease status, including staging based on TNM 
staging system or Ann-arbor, treatment response 
evaluation (<6 months by the end of chemotherapy 
and <2 months by the end of radiation therapy) based 
on PERCICST or Deauville score, restaging, and 
recurrence were then determined according to the 
patients’ medical chart and baseline imaging, 
including PET/CT data, with and without considering 
PET-detected cerebral metastasis. Brain metastasis 
was considered as a focus or foci of abnormal 
increased or decreased radiotracer accumulation 
more or less than 20% of the surrounding tissue or 
the opposite side with or without associated 
morphologic abnormality on CT component 
including edema, midline shift or abnormal density. 
Single (<3) vs. multiple (≥3) metastasis were 
determined on the basis of the impact on treatment 
strategy.  
Standard of reference: Forty-Six PET/CT detected 
brain metastasis were correlated with the results of 
clinical formal follow up (n=38, 82.6%), surgical 
biopsy (n=5, 10.87%) and MRI/MRS 3 (6.52%). 
Based on the oncologist final decision, the impact of 
true positive PET-detected brain metastasis on cancer 
status were then investigated. 
Statistical Analysis: Descriptive quantitative 
variables were expressed as either frequency or mean 
(±SD). Chi-square test was used to compare change 
in disease status and treatment strategy among 
primary cancer types and indication. p value <0.05 
was considered to indicate a statistically significant 
difference (SPSS 23). 
Results 
Demographics: Of 46 patients with a total of 96 
lesions, 44 (1.12%) patients were finally verified to 
have at least one cerebral metastatic lesion (positive 
predictive value=95.65%) (25 female [56.8%), 19 
male [43.2%]; mean age 59.25±11.87 years). Eighty-
seven point five patients were >50 years old. Mean 
age did not show significant different between male 
(61.10±10.91 years) and female (57.84±13.10) 
(p=0.36).  
Image characteristics: The most common metabolic 
pattern of cerebral metastasis was focus of abnormal 
increased radiotracer uptake (n=40, 90.9%). Three out 
of 6 (50%) cerebral metastasis of colorectal and 1 of 
prostate origin presented with foci of absent metabolic 
activity. Twenty six patients (59.1%) had single lesion 
(<3) and the remainder demonstrated multiple lesions 
(40.9%). Except for breast cancer, most primary 
cancer revealed single cerebral metastasis at PET/CT 
scan. Most lesions did not have any abnormal CT 
associated abnormality (n=52, 54.16%), while 37 
(38.54%) had edema, 5 (5.2%) demonstrated midline 
shift and 2 presented with hemorrhage (2.2%). The 
anatomical distribution pattern of the new cerebral 
lesions were as the following: supratentorial n=81 
(84.37%), infratentorial n=9 (9.37%) and both supra 
and infratentorial lesion n=6 (6.25%). No significant 
different was found in imaging characteristics of 
cerebral metastasis based on primary cancer type and 
clinical indication. Table 1 summarized the imaging 
characteristics of PET-detected cerebral metastasis 
based on primary cancer type and indication. 
Detection Rate in General: The overall detection rate 
of new cerebral metastasis was found to be 44 out of 
3933 (1.12%). The most frequent primary source of 
PET-detected brain metastasis were lung cancer 
(19/385, 4.93%), followed by cancer of unknown 
primary (5/168, 2.97%), breast cancer (8/468, 1.71%), 
genitourinary cancer 4/427 (0.94%), colorectal cancer 
6/695 (0.86%) and lymphoma 2/859 (0.23%). 
Detection Rate based on primary cancer type: 
Previously unidentified brain metastasis in patients 
with lung cancer were most frequently recognized at 
staging (11/19, 57.89%) and resting (6/19, 31.57%) 
exams. In breast cancer, the highest yield obtained at 
restaging studies (6/8, 75%). New cerebral metastasis 
in patients with colon cancer was most frequently seen 
in patients underwent treatment response evaluation 
(4/6, 66.66%). 
Detection Rate based on clinical indication: On a 
per indication basis, new cerebral metastasis was most 
frequently identified at initial restaging (n=16/44, 
36.36%), followed by staging (n=14/44, 31.82%), and 
treatment response evaluation (n=9/44, 20.45%). The 
most common primary cancer harbouring unidentified 
cerebral metastatic lesion at initial staging was lung 
(n=11/17, 64.7%). At restaging, the highest detection 
Bakhshaieshkaram et al.                                                          Brain-included 18F FDG PET/CT Acquisition Protocol … 
NBM                                                                                      24                                       Novelty in Biomedicine 2018, 1, 21-8 
rate occurred in lung (n=6/16, 37.5%) and breast 
cancer (n=6/16, 37.5%). Treatment response 
evaluation using brain-included PET/CT 
demonstrated the highest yield in colon and lung 
cancers (n=4/9, 44.44% and 2.9, 22.22%, 
respectively).  
Change in Disease Status: Newly detected cerebral 
metastasis changed cancer status in 12 patients 
(12/44, 27.3% per patients with unidentified cerebral 
lesion, 12/3933, 0.3% per total patients) as upstaging 
in 10/33 (30.30%) and under treatment progressive 
disease in 2/9 (22.22%). 
Change in Disease Status based on primary 
cancer type: Change in disease status most 
frequently occurred in patients with lung (4/12, 
33.33% per cohort with change in disease status, 
4/19, 21.05% per patients with lung cancer and brain 
metastasis) and breast cancer (3/12, 25% per cohort 
with change in disease status, 3/8, 37.5% per patients 
with lung cancer and brain metastasis). In all 2 patients 
with lymphoma harbouring unidentified cerebral 
lesion, disease status changed at initial exam and post 
treatment studies.  
Change disease status based on indication: Brain-
included PET/CT study demonstrated the highest 
impact on disease status at restaging exams (7/16, 
43.75%) in breast cancer (n=3/7, 42.85%) and lung 
cancer (n=2/7, 28.75%), followed by staging (3/17, 
17.64%) in lung cancer. brain-included PET/CT 
changed disease status while evaluating treatment 
response in only 2 patients, one of them had lung 
cancer (n=1, 50%).  
Table 2 outlined cancer characteristics in cohort with 
PET-detected cerebral metastasis based on primary  














(no. %)  
Metabolic pattern 
Increased 19 8 5 3 3 2 40 (90.9%) 
Decreased 0 0 0 1 3 0 4 (9.1%) 
CT associated abnormality 
Edema 4 6 2 2 2 1 17 (38.6%) 
Midline Shift 3 0 0 0 0 0 3 (6.8%) 
Hemorrhage 0 0 0 1 0 0 1 (2.3%) 
No 12 2 3 1 4 1 23 (52.3%) 
Location 
Supratentorial 17 5 4 4 5 2 37 (84.1%) 
Infratentorial 2 2 0 0 0 0 4 (9.1%) 
Both 0 1 0 2 1 0 3 (6.8%) 
Number of Lesion 
<3 12 1 3 3 5 2 26 (59.1%) 
3≤ 7 7 2 1 1 0 18 (40.9%) 
*CUP= cancer of unknown primary 
**GYN= genitourinary cancer 
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Table 1: Mean, standard deviation, minimum and maximum age of participants in test and control groups. 
 Lung Breast  Colorectal Lymphoma CUP* GYN** Total  
Detection 
Rate 


























































Diagnosis 0 0 0 0 5  
(100%) 
0 5 (11.36%) 











Change in Disease Status  
Initial Staging 1 
(9.1%) 
(33.3%) 



























0 0 1  
(100%) 
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0  2 (16.16%) 
Diagnosis 0 0 0 0 0 0 0 
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*CUP= cancer of unknown primary 
**GYN= genitourinary cancer 
+First row: within primary cancer type 
++Second row; within indication 
 
cancer type and clinical indication. 
Figure 1 illustrated a focus of abnormal increased 
FDG uptake in right cerebellar hemisphere, 
compared to the opposite side, incidentally detected 
by brain-included PET/CT study in a 57 Y/O women 
with a history of breast cancer in right breast 
underwent radical mastectomy being work up for 
restaging. All baseline imaging were negative for 
distant malignant lesion. PET/CT with standard field 
of view were also negative for active malignant 
lesion. Brain MRI (not shown) demonstrated a 
hypointense lesion on T1 with a uniform enhancing 
pattern which demonstrated high signal intensity on 
T2 images. 
Discussion 
The results of the present study provided evidence 
for the potential value of brain included PET/CT 
study in patients with lung cancer, regardless the 
clinical indication, cancer of unknown primary and 
patients with breast cancer at restaging examination. 
This study found no clinically significant role for 
brain-included PET/CT scan in most other cancer 
types, including patients with lymphoma which 
constitute the highest percentage of patient 
population at most PET/CT centers.  
The additional value of brain-included PET/CT study 
in neurologically asymptomatic extracerebral cancer 
patients still needs to be verified. The results of the 
preliminary studies revealed that the detection rate of 
cerebral metastasis using brain-included PET/CT was 
as low as 1% 3 which was mainly attributed to the 
inherently low sensitivity of 18 F FDG PET/CT due 
to high physiologic 18 F FDG uptake. The results of 
the present study demonstrated an overall detection 
rate of less than 1% for brain metastasis in most 
primary cancer type by the application of brain-
included PET/CT study which is in line with 
literature6,7,9,11. However, some major confounding 
factors may contribute in this suboptimal 
performance. The results of large-scaled 
epidemiologic studies have been demonstrated that 
most primary cancer types often being evaluated with 
PET/CT study, including lymphoma, bladder, ovary 
and prostate, soft tissue sarcoma less commonly 
metastasize to the brain 12 which may be responsible 
for the overall low detection rate of cerebral metastasis 
at true whole body PET/CT scan. However, this may 
not be true for certain primary malignancies. Using 
true whole body PET/CT, current study revealed that 
previously unidentified brain metastasis was 
successfully detected in approximately 5% of patients 
with lung cancer, in 21.05% of whom served as the 
only site of distant metastasis. 
Several studies have been demonstrated that up to 90% 
of brain metastasis developed within the first year of 
diagnosis of primary cancer, more than half of which 
were diagnosed during the first month 13and hence 
presumably may consider a key role for neuroimaging 
modalities at initial staging of patients with lung 
cancer. In line with literatures, the current results 
provide evidence for the potential value of brain-
included PET/CT at initial staging of lung cancer. 
Additionally, the application of brain-included 
 
 
Figure 1. Right cerebellar metastasis incidentally detected in a 57 
Y/O women with breast cancer and correlated with MRI, being 
work up for subsequent treatment strategy. a) PET and fused 
PET/CT in axial view (b-d) demonstrated focal intense F-18 FDG 
uptake with no corresponding on NECT images. 
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PET/CT scan at restaging examination may be 
beneficial regarding a 10% 5-year cumulative 
incidence of brain metastasis.  
In patients with breast cancer, as the second most 
common primary origin of cerebral metastasis, the 
highest yield of true whole body 18 F FDG PET/CT 
was obtained at restaging examination. These results 
are compatible with literature indicating that the 
highest incidences of brain metastasis in breast 
cancer are observed after 2 year of initial diagnosis13. 
Regarding little penetration rate of most 
chemotherapeutic agent, cerebral parenchyma may 
be the first site of disease recurrence and progression 
in patent’s with breast cancer14, provide additional 
confirmatory evidence for the potential value of 
brain-included PET/CT study at restaging 
examination in this cohort. 
The most common primary origin in patients with 
cancer of unknown primary has been shown to be 
lung cancer15 which have a significant association 
with brain metastasis in this clinical setting16. Current 
study revealed that in nearly 3% of patients with 
cancer of unknown origin, true whole body PET/CT 
scan correctly identified new brain metastasis and 
may hence provide potentially valuable prognostic 
information to exclude a small minority of patients 
with favorable prognosis17.  
There results for other type of primary cancer 
showed major heterogeneity. Indeed, only for breast 
and lung carcinoma sufficient data was available 
allowed further analysis. Some reports demonstrated 
kidney and bladder tumor as the most prevalent 
primary origin of brain metastasis (0-11%, and 
5.26%- 5.9%, respectively)6,7,9,11, however, it was not 
demonstrated in the current study. In addition, brain-
included field of view in colorectal cancer had a poor 
yield (0.86) which was in line with other similar 
publication (0- 0.7%)6,7,9,11. Despite a relatively large 
patients’ population, the detection rate of newly 
diagnosed brain metastasis in patients with 
lymphoma was not of clinical significance (0.23%).  
There are some major drawbacks in the current 
study. The clinical impact of newly PET-detected 
brain metastasis on change in treatment strategy and 
survival was not evaluated in this study. The added 
value of PET-detected brain metastasis in primary 
cancer other than lung, breast and cancer of unknown 
primary still needs to be verified by large-scale 
multicenteric studies. Furthermore, the potential role 
of clinical risk factors of brain metastasis, including 
the histologic subtype, tumor grading, specific tumor 
mutation and receptor expression in patients’ 
stratification for brain-included PET/CT did not 
investigated in the current study.  
Conclusion 
Patients’ stratification for brain-included PET/CT 
study may be best achieved considering primary 
cancer type and timing for evaluation. Regarding a 
significant detection rate of cerebral metastasis, brain 
included PET/CT study may be recommended as the 
standard acquisition protocol in patients with lung 
cancer, regardless the clinical indication, cancer of 
unknown primary and breast cancer at restaging 
examination. Providing little additional information, 
brain-included field of view should not be applied as a 
routine practice for other primary cancer types, 
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